Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02456103 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis
A Phase 3 study, sponsored by PTC Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 246
- Enrollment target
NCT02456103 is a Phase 3 study that was terminated before completion, run by PTC Therapeutics. The registered enrollment target is 246 participants.
The verdict
NCT02456103, a Phase 3 study, was terminated before completion, sponsored by PTC Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 246 participants
- Enrollment target
Study Summary
This is an open-label extension study for participants who completed a Phase 3, placebo-controlled study of ataluren in participants with nonsense mutation cystic fibrosis (nmCF) not receiving chronic inhaled aminoglycosides.
Interventions
- DRUG Ataluren
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2015-08-31 |
| Est. Completion | 2017-06-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02456103
The ClinicalTrials.gov registry entry for NCT02456103 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PTC Therapeutics, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ataluren is the first listed.
NCT02456103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02456103 about?
NCT02456103 is a clinical study titled "Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis". This is an open-label extension study for participants who completed a Phase 3, placebo-controlled study of ataluren in participants with nonsense mutation cystic fibrosis (nmCF) not receiving chronic inhaled aminoglycosides.
What is the current status of trial NCT02456103?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 246 participants. The study started on 2015-08-31. Estimated completion is 2017-06-02.
What interventions are being tested in trial NCT02456103?
The interventions under investigation include: Ataluren (DRUG).
Who is sponsoring clinical trial NCT02456103?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.